Glomerular diseases and transplantation: Similarities in pathogenetic mechanisms and treatment options

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 35-41

  Ponticelli, Claudio ^a   Coppo, Rosanna ^b   Salvadori, Maurizio ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

B cells; glomerulonephritis; innate immunity; renal transplantation; treatment

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; COMPLEMENT SYSTEM; DENDRITIC CELL; GLOMERULONEPHRITIS; GLOMERULOPATHY; INNATE IMMUNITY; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; KIDNEY TRANSPLANTATION; PROGNOSIS;

EID: 78650635157     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq574     Document Type: Article

References (80)

1. Mogensen TH. Pathogen recognition and inflammatory signalling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-273
2. Rasmussen SB, Reinert LS, Paludan SR. Innate recognition of intra-cellular pathogens: detection and activation of the first line of defense. APMIS 2009; 117: 323-337
3. Mellanby RJ, Thomas DC, Lamb J. Role of regulatory T-cells in auto-immunity. Clin Sci 2009; 116: 639-649
4. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005; 42: 859-867
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-376
6. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161
7. Anders HJ, Schlöndorff D. Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 2007; 16: 177-183
8. Anders HJ, Zecher D, Schlöndorff D. Microbial nucleic acids in the pathogenesis of glomerulonephritis. Nephrol Ther 2006; 2: 422-431
9. Santiago-Raber ML, Baudino L, Izui S. 16 Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun 2009; 33: 231-238
10. Lartigue A, Colliou N, Calbo S et al. Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol 2009; 183: 6207-6212
11. Brown HJ, Sacks SH, Robson MG. Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J Am Soc Nephrol 2006; 17: 1931-1939
12. Suzuki Y, Tomino Y. The mucosa-bone-marrow axis in IgA nephro-pathy. Contrib Nephrol 2007; 157: 70-79
13. Suzuki H, Suzuki Y, Narita I et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008; 19: 2384-2395
14. Coppo R, Camilla R, Amore A et al. Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immuno-globulin A nephropathy. Clin Exp Immunol 2010; 159: 73-81
15. Banas MC, Banas B, Hudkins KL et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19: 704-713
16. Pawar RD, Castrezana-Lopez L, Allam R et al. Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology 2009; 128: 206-221
17. Anders H-J, Schlondorff DO. Innate immunity receptors and auto-phagy: implications for autoimmune kidney injury. Kidney Int 2010; 78: 29-37
18. Li M, O'Sullivan KM, Jones LK et al. CD100 enhances dendritic cell and CD4+ cell activation leading to pathogenetic humoral responses and immune complex glomerulonephritis. J Immunol 2006; 177: 3406-3412
19. Fujinaka H, Nameta M, Kovalenko P et al. Periglomerular accumulation of dendritic cells in rat crescentic glomerulonephritis. J Nephrol 2007; 20: 357-363
20. Saiga K, Tokunaka K, Ichimura E et al. NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cyto-plasmic antibody in SCG/Kj mice. Arthritis Rheum 2006; 54: 3707-3715
21. Fiore N, Castellano G, Blasi A et al. Immature myeloid and plasma-cytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol 2008; 45: 259-265
22. Tucci M, Calvani N, Richards HB et al. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann NY Acad Sci 2005; 1051: 421-432
23. Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20: 538-544
24. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34: J276-J286
25. Oortwijn BD, Rastaldi MP, Roos A et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22: 3191-3195
26. Nauta AJ, Castellano G, Xu W et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 17: 3044-3502
27. Lood C, Gullstrand B, Truedsson L et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythe-matosus pathogenesis. Arthritis Rheum 2009; 60: 3081-3090
28. Obhrai J, Goldstein DR. The role of Toll-like receptors in solid organ transplantation. Transplantation 2006; 81: 497-502
29. Land W. Innate alloimmunity: history and current knowledge. Exp Clin Transplant 2007; 5: 575-584
30. Castellano G, Melchiorre R, Loverre A et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion- induced renal damage. Am J Pathol 2010; 176: 1648-1659
31. Nyirenda MH, O'Brien K, Sanvito L et al. Modulation of regulatory T cells in health and disease: role of Toll-like receptors. Inflamm Allergy Drug Targets 2009; 8: 124-129
32. Kim JI, Lee MK 4th, Moore DJ et al. Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance. Am J Transplant 2009; 9: 2736-2744
33. Van der Touw W, Bromberg JS. Natural killer cells and the immune response in solid organ transplantation. Am J Transplant 2010; 10: 1354-1358
34. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053-2060
35. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
36. Prunotto M, Carnevali ML, Candiano G et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21: 507-519
37. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817
38. Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470
39. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4din renal allograft is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380
40. Tillou X, Poirier N, Le Bas-Bernardet S. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmu-nized baboons. Kidney Int 2010; 78: 152-159
41. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-415
42. Gaston RS, Cecka JM, Kasiske BL. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74
43. Zou Y, Stastny P, Süsal C et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300
44. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465
45. Fukami N, Ramachandran S, Saini D et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182: 309-318
46. Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando) 2010; 24: 67-78
47. Okitsu T, Bartlett ST, Hadley GA et al. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 2001; 1: 138-145
48. Chang AT, Platt JL. The role of antibodies in transplantation. Transplant Rev (Orlando) 2009; 23: 191-198
49. Coppo R, Camilla R, Alfarano A et al. Upregulation of the immuno-proteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int 2009; 75: 536-541
50. Sahali D, Pawlak A, Le Gouvello S et al. Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol 2001; 12: 1648-1658
51. Ristola M, Arpiainen S, Saleem MA et al. Regulation of Neph3 gene in podocytes-key roles of transcription factors NF-kappaB and Sp1. BMC Mol Biol 2009; 10: 83
52. Neubert K, Meister S, Moser K et al. The proteasome inhibitor borte-zomib depletes plasma cells and protects mice with lupus-like disease from nephritis. 2008; 14: 748-755
53. Van der Vlag J, Berden JH. Proteasome inhibition: a new therapeutic option in lupus nephritis? Nephrol Dial Transplant 2008; 23: 3771-3772
54. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284
55. Palmer DCS, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009; 30: 592-602
56. Gómez-Guerrero C, López-Franco O et al. Suppressors of cytokine signaling regulate Fc receptor signaling and cell activation during immune renal injury. J Immunol 2004; 172: 6969-6977
57. Hernández-Vargas P, López-Franco O et al. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 2005; 16: 1673-1683
58. Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010; 21: 763-772
59. Edemir B, Kurian SM, Eisenacher M et al. Activation of counter-regulatory mechanisms in a rat renal acute rejection model. BMC Genomics 2008; 9: 71
60. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
61. Russ G, Segoloni G, Oberbauer R et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80: 1204-1211
62. Salvadori M, Scolari MP, Bertoni E et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicen-ter, randomized, controlled trial. Transplantation 2009; 88: 1194-1202
63. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242
64. Krämer S, Wang-Rosenke Y, Scholl V et al. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008; 294: F440-F449
65. Vogelbacher R, Wittmann S, Braun A et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499
66. Tsagalis G, Psimenou E, Iliadis A et al. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases. Am J Kidney Dis 2009; 54: 340-344
67. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326-333
68. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythe-matosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233
69. Looney JR. B cell-targeted therapies for systemic lupus erythematosus. An update of clinical trial data. Drugs 2010; 70: 529-540
70. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168
71. Bomback AS, Derebail VK, McGregor JG et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4: 734-744
72. Segarra A, Praga M, Ramos N et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009; 4: 1083-1088
73. Guigonis V, Dallocchio A, Baudouin Vet al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23: 1269-1279
74. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008; 20: 602-606
75. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095-1102
76. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998-1005
77. Stegall MD, Gloor J. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8-10
78. Just SA, Marcussen N, Sprogøe U et al. Acute antibody-mediated rejection after ABO-incompatible kidney transplantation treated successfully with antigen-specific immunoadsorption. Nephrol Dial Transplant 2010; 25: 310-313
79. Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009; 23: 63-73
80. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235